Results 21 to 30 of about 25,289 (245)

Comparison of the effects of giving captopril and valsartan in cases of heart failure for people with congenital heart disease [PDF]

, 2020
Background: Congenital Heart Disease (CHD) has a prevalence ranging from 6 to 10 per 1000 live births, with an average of 8 out of 1000 live births. One of the pathological consequences of CHD is heart failure.
Marta Lastijani Sigit, -, I Ketut Alit Utamayasa, -, Mahrus A. Rahman, -   +2 more
core   +1 more source

Valsartan in Combination with Tripterygium Glycosides Protects against Chronic Nephritis via the Toll-Like Receptor 4 Pathway

Analytical Cellular Pathology, 2022
Objective. Valsartan has been studied to exert effects on kidney disease. However, the concrete function of valsartan in combination with tripterygium glycosides in chronic nephritis remained largely unknown. The study was designed to unravel the impacts
Jiabao Dong, Duo Huang, Ling Jing, Mengmeng Wu   +3 more
doaj   +1 more source

1,2‐Bis(boronate) Arenes by Borylation Directed Borylation

Angewandte Chemie, EarlyView.
Boron electrophiles derived from tetrabromo‐pyrazaboles and AlCl3 affect the regioselective vicinal double C–H borylation of a range of arenes and polycyclic aromatic hydrocarbons (PAHs). A subsequent pinacol installation step then affords the vicinal bis‐boronate ester‐substituted arene/PAH.
Anna V. Schellbach, Mathew J. Cross, Emily Noone, Cate S. Anstöter, Michael J. Ingleson   +4 more
wiley   +2 more sources

Effect of Sacubitril-Valsartan on Restoration and Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation

Frontiers in Cardiovascular Medicine, 2022
BackgroundExisting studies have shown that sacubitril-valsartan ameliorated atrial remodeling in atrial fibrillation (AF) and favored maintenance of sinus rhythm in patients with AF and heart failure.
Qingsong Chen, Yunlin Chen, Fang Qin, Huaan Du, Chunxia Gan, Bei Zhou, Na Wang, Mingyang Xiao, Zhenhong Ou, Wei Zhao, Ben Cui, Zengzhang Liu, Yuehui Yin   +12 more
doaj   +1 more source

Pharmacokinetic interaction study between ligustrazine and valsartan in rats and its potential mechanism

Pharmaceutical Biology, 2020
Context Ligustrazine and valsartan are commonly used drugs in the treatment of cardiac and cardiovascular disease. Objective The interaction between ligustrazine and valsartan was studied to investigate the effect of ligustrazine on the pharmacokinetics ...
Yang Liu, Jiaqi Zhang, Di Wu, Liran Cui
doaj   +1 more source

What the near Future Holds for Sacubitril/Valsartan: A Summary of Major Ongoing Studies

Journal of Cardiovascular Development and Disease, 2022
Early research on neprilysin inhibition showed that sacubitril/valsartan, a combination of the valsartan and the neprilysin inhibitor sacubitril, was superior to enalapril in patients with heart failure with reduced ejection fraction (HFrEF) in the ...
Hisham A. Badreldin, Nasser Aldosari, Lama Alnashwan, Taif Almutairi, Nada Yousif, Khalid Alsulaiman, Ohoud Aljuhani, Awatif Hafiz, Omar Alshaya   +8 more
doaj   +1 more source

Aerosil in Solid-state Buccal Film for Improved and Sustained Delivery of Valsartan: Molecular Docking Studies [PDF]

Chemical and Biochemical Engineering Quarterly, 2023
To overcome low oral bioavailability and short biological half-life, improved and sustained buccal delivery of valsartan has been proposed. Valsartan film with colloidal silicon dioxide has been prepared using HPMC as mucoadhesive polymer matrix by ...
R. Swain, S. Nandi, P. Bardhan, S. S. Swain, S. Mohapatra, S. Mallick   +5 more
doaj   +1 more source

Valsartan induced exanthematous macular skin lesions [PDF]

, 2020
Valsartan is one of the antihypertensive agents under angiotensin II receptor blocker (ARB) group that commonly used in treating hypertensive patient with underlying heart failure, chronic kidney disease and angiotensin converting enzyme inhibitor (ACE-i)
Che' Man, Mohamad, Mohd Arifin, Siti Roshaidai, Amirruddin, Salman, Che Alhadi, Shahidah, Azmi, Nurul Husna, Amiruddin, Salman   +5 more
core   +2 more sources

Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene, Sujung Choi, Steven J. Lippmann, Robert J. Mentz, Melissa A. Greiner, N. Chantelle Hardy, Bradley G. Hammill, Nancy Luo, Marc D. Samsky, Paul A. Heidenreich, Warren K. Laskey, Clyde W. Yancy, Pamela N. Peterson, Lesley H. Curtis, Adrian F. Hernandez, Gregg C. Fonarow, Emily C. O'Brien   +16 more
doaj   +1 more source

Efficacy and Safety of a Single-Pill Triple Combination of Valsartan, Amlodipine, and Chlorthalidone in Patients With Essential Hypertension Inadequately Controlled on Dual Therapy With Valsartan and Amlodipine: A Randomized, Double-Blind, Multicenter, Phase 3 Trial. [PDF]

J Clin Hypertens (Greenwich)
ABSTRACT Many hypertensive patients require three or more antihypertensive agents to achieve target blood pressure. This randomized, double‐blind, multicenter phase 3 trial conducted in South Korea evaluated the efficacy and safety of a single‐pill triple combination therapy with valsartan (Val), amlodipine (Aml), and chlorthalidone (CTD) in patients ...
Cho IJ, Hong SJ, Kong MG, Jo SH, Cho EJ, Choi CU, Choi JH, Kim DH, Kim JH, Ihm SH, Pyun WB.   +10 more
europepmc   +2 more sources